Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematologic transplantation and translational medicines because both the […]
Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by […]
Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo […]
Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed year where clinical progress, continued growth, and segmentation into new disease areas affecting larger […]
In the past decade, emerging therapeutic modalities like cell and gene therapies have opened up new treatment options for previously intractable diseases, changing the industry needs for primary tissues. While […]
Welcome to the second installment of our FAQ blog series! Today, we are looking at differences between CD34+ cells isolated from different tissue sources to provide a better understanding of […]
Copyright ©
AllCells. All rights reserved.
